As an illustrative example, the Kalluri group discovered that glypican 1 (GPC1)+ exosomes carrying the KRAS mutation in pancreatic cancer patients precisely mirrored mutations found in the tumor tissues, underscoring the heightened specificity exosomes can offer over traditional serum or plasma measurements. This evidence concerns the gene GPC1 and familial pancreatic carcinoma.